Antibody Response to SARS-CoV-2 Vaccination in Patients With Lymphoproliferative Disorders and Plasma Cell Dyscrasias: Anti-Lymphoma Therapy as a Predictive Biomarker of Response to Vaccination

Antibody Response to SARS-CoV-2 Vaccination in Patients With Lymphoproliferative Disorders and Plasma Cell Dyscrasias: Anti-Lymphoma Therapy as a Predictive Biomarker of Response to Vaccination

We retrospectively analyzed SARS-CoV-2 vaccination antibody responses in a cohort of 273 patients with lymphoproliferative disorders or plasma cell dyscrasias who were seen at a single tertiary cancer center. Semi-quantitative anti-spike protein serologic testing was performed with enzyme immunoassa...

Full description

Bibliographic Details
Main Authors: Carol Gung, Regina McGuire, Mercy George, Abdullateef Abdulkareem, Katherine A. Belden, Pierluigi Porcu, Ubaldo Martinez-Outschoorn, Adam F. Binder, Inna Chervenova, Onder Alpdogan
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-07-01
Series:Frontiers in Oncology
Subjects:
vaccination
Covid-19
immune response
hematologic malignancies
chemotherapy.
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.840451/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.840451/full

Similar Items